In addition to vaccination programmes, the SARS-CoV-2 pandemic requires safe and efficient treatment options...
COVID-19
Apogenix has entered the global fight against COVID-19. Lead immunotherapy candidate asunercept (APG101) is...
The current COVID-19 pandemic situation has shown that repurposing drugs can be crucial for delivering new...
Development of the large-scale vaccine production process remains an inherently challenging undertaking. Given...
Pfizer and Biontech SE have reached an agreement with the European Commission to supply 200 million doses of...
Interim data on BioNtech’s/Pfizer’s COVID-19 vaccine candidate BNT162b2 suggest an efficacy of more than 90% -...
Boehringer Ingelheim announced the start of Phase II studies of its oral TRPC6 blocker code-named BI 764198 in...
Share
